KCM
REGN icon

Kendall Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kendall Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63M Sell
2,116
-9
-0.4% -$6.89K 0.34% 77
2025
Q4 		$1.64M Buy
2,125
+1
+0% +$679 0.34% 70
2025
Q3 		$1.19M Sell
2,124
-4
-0.2% -$2.26K 0.27% 94
2025
Q2 		$1.12M Sell
2,128
-84
-4% -$46.9K 0.3% 92
2025
Q1 		$1.4M Sell
2,212
-115
-5% -$79.1K 0.41% 64
2024
Q4 		$1.66M Sell
2,327
-20
-0.9% -$16.8K 0.48% 59
2024
Q3 		$2.47M Sell
2,347
-70
-3% -$77.9K 0.76% 38
2024
Q2 		$2.54M Sell
2,417
-70
-3% -$67.9K 0.85% 29
2024
Q1 		$2.39M Sell
2,487
-210
-8% -$200K 0.82% 31
2023
Q4 		$2.37M Sell
2,697
-75
-3% -$61.8K 0.92% 27
2023
Q3 		$2.28M Sell
2,772
-253
-8% -$199K 1.01% 24
2023
Q2 		$2.17M Sell
3,025
-55
-2% -$42.4K 0.95% 26
2023
Q1 		$2.53M Buy
3,080
+572
+23% +$431K 1.22% 18
2022
Q4 		$1.81M Sell
2,508
-10
-0.4% -$7.38K 0.91% 28
2022
Q3 		$1.74M Sell
2,518
-9
-0.4% -$5.67K 1.01% 24
2022
Q2 		$1.49M Buy
2,527
+234
+10% +$152K 0.82% 39
2022
Q1 		$1.6M Buy
2,293
+10
+0.4% +$6.33K 0.77% 37
2021
Q4 		$1.44M Sell
2,283
-72
-3% -$44.3K 0.68% 43
2021
Q3 		$1.43M Sell
2,355
-43
-2% -$26.7K 0.77% 41
2021
Q2 		$1.34M Hold
2,398
– – 0.75% 44
2021
Q1 		$1.14M Buy
2,398
+122
+5% +$59.4K 0.7% 46
2020
Q4 		$1.1M Buy
2,276
+110
+5% +$59.4K 0.8% 43
2020
Q3 		$1.21M Sell
2,166
-75
-3% -$45.5K 1.05% 33
2020
Q2 		$1.4M Sell
2,241
-70
-3% -$39.7K 1.34% 22
2020
Q1 		$1.13M Sell
2,311
-165
-7% -$68.1K 1.28% 25
2019
Q4 		$930K Buy
2,476
+483
+24% +$163K 0.73% 51
2019
Q3 		$553K Buy
1,993
+250
+14% +$74K 0.49% 70
2019
Q2 		$546K Buy
1,743
+414
+31% +$138K 0.49% 71
2019
Q1 		$546K Buy
1,329
+471
+55% +$194K 0.52% 63
2018
Q4 		$320K Buy
858
+189
+28% +$69.2K 0.33% 81
2018
Q3 		$270K Buy
+669
New +$255K 0.23% 98

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Kendall Capital Management's REGN Position: Q1 2026 in Review

Kendall Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 0.42% in Q1 2026, selling an estimated $6.89K and leaving 2,116 shares worth $1.63M. The position accounts for 0.34% of the portfolio, ranked #77.

Kendall Capital Management first reported a position in REGN in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.54M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Kendall Capital Management held 2,116 shares of Regeneron Pharmaceuticals worth $1.63M as of Q1 2026.
  • Kendall Capital Management sold 9 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.89K.
  • Regeneron Pharmaceuticals made up 0.34% of Kendall Capital Management's portfolio in Q1 2026, its #77 holding.
  • Kendall Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Kendall Capital Management's Regeneron Pharmaceuticals position peaked at $2.54M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.